Keyword: Michael Quirmbach

News

CordenPharma Invests €900 Million in Peptide Platform Expansion

16.07.2024 -

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.

Markets & Companies

Expert Interview: Michael Quirmbach, CordenPharma

16.10.2020 -

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has...

Strategy & Management

Experts Statements: Michael Quirmbach, CordenPharma

05.09.2019 - The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manu...

News

Michael Quirmbach Appointed as CEO and President of CordenPharma

26.07.2019 - CordenPharma has appointed Michael Quirmbach as its new CEO and president, effective Aug. 1, 2019. He is going to succeed Riku Rautsola who will transition to the role of a senior...

Research & Innovation

Experts Statements: Dr. Michael Quirmbach, Corden-Pharma International

12.12.2016 - Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs...

Research & Innovation

The Winning Formula

06.12.2016 - Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs...

Trends in Chemical & Pharmaceutical Research

26.09.2016 - Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs...

Strategy & Management

The Winning Formula

08.09.2016 - Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs...